Cardiac hypertrophy is an adaptive response to an increase in blood pressure which, despite initial benefits, leads to heart failure and is an independent risk factor for cardiovascular disease. In January Nature Medicine, Masanori Asakura and colleagues from Osaka University Faculty of Medicine, Osaka, Japan show that shedding of heparin-binding epidermal growth factor (HB-EGF) by ADAM12 plays an important role in the development of cardiac hypertrophy.Asakura et al. found that in cultured rat
Cardiac hypertrophy is an adaptive response to an increase in blood pressure which, despite initial benefits, leads to heart failure and is an independent risk factor for cardiovascular disease. In January
Asakura
"These results show that inhibition of HB-EGF shedding could be a potent therapeutic strategy for cardiac hypertrophy," said James Liao of Brigham ...
Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.
View this Issue
Experts from the Women’s Brain Foundation and bit.bio will explore the importance of sex-specific in vitro models for neurological research and drug discovery.
Discover how scientists are designing the next groundbreaking vaccines against infectious diseases.
In this webinar, Linghua Wang and Jeremy Goecks will talk about technology that enables new approaches for a better understanding of tumors on a cellular, spatial, and environmental level.
Explore how researchers use organoids to understand tissue regeneration and develop novel therapies.
Collaborative project with world leader in AI computing demonstrates Artificial workflows and model integration for self-driving generative virtual screening in drug discovery. Company also announces key accreditations in recognition of excellence in data security, AI innovation, and commitment to continuous improvement.
Partnership complements Sapient’s mass spectrometry-based proteomics services, extends multi-omics solutions, and will enable development of NULISAseq™ assays under regulated guidance
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of Vericheck ddPCR™ Empty-Full Capsid Kits for adeno-associated virus (AAV) serotypes 2 and 8, enabling determination of capsid titer, genome titer, and percentage of full capsids in purified or unpurified (crude lysate) samples.
Tailored nucleic acid extraction and amplification methods help scientists overcome the challenges of detecting Mycoplasma contamination in advanced therapy medicinal products.
